Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide
TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received independent Institutional Review Board (IRB) approval for the Phase II trial of its lead drug LSALT peptide (Metablok) targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.
Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide
TORONTO, July 28, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that it has chosen its first U.S. clinical site for the Phase II trial of its lead drug LSALT peptide (Metablok).
Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.
Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19)
Novel Mechanism of Action - a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage
Investigational New Drug application activated and U.S. FDA permission to proceed with Phase II trial to treat complications in COVID-19 patients.
Phase 1 study in 52 healthy male and female volunteers is complete with LSALT peptide meeting primary endpoint of safety and tolerability.